
    
      Patients will receive a sub-Tenon injection of 15mg of Anecortave acetate in their study eye
      with the use of a counter pressure device. Patients will then be followed for up to 24
      months. The patients will have the option of extending their participation in the study for
      an additional 24 months. Statistical analysis will include comparison of patient follow-up
      visual acuity and angiographic data.
    
  